Skip to main content
SpringerLink
Log in

Optimal Management of Behavioural Disorders Associated with Dementia

  • Review Article
  • Disease Management
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Behavioural disorders occur with great frequency in patients with dementia. They are the major reason for admission of these patients to nursing homes. However, there have been few controlled trials of many of the commonly used drugs to guide therapy. To treat these conditions successfully, an adequate description of target symptoms of the behaviours to be corrected and a thorough investigation to identify precipitating causes are essential.

Behavioural problems in dementia patients may result from physical illnesses, adverse drug effects, environmental changes, psychiatric syndromes (i.e. depression, delirium or psychosis) or the dementing illness itself. Therapeutic strategies should address the underlying cause whenever possible. Although pharmacological therapies are commonly employed, their efficacy is often modest and adverse effects can be quite significant. Ongoing reassessments are essential to maximise symptomatic benefits and minimise adverse effects. Several trials with different drugs are often necessary before an effective therapy is found. Anticholinergic adverse effects, which occur commonly with many antipsychotic and antidepressant medications, may worsen the cognitive and memory deficits that form the primary symptoms of dementia in these patients.

This article summarises the use of the various psychoactive medications that target common behavioural disturbances, including agitation, psychosis, depression and sleep disturbances, in dementia patients. General guidelines regarding dosage, potential adverse effects and duration of therapy are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer’s disease in a community population of older persons: higher than previously reported. JAMA 1989; 262: 2551–6

    Article  PubMed  CAS  Google Scholar 

  2. Rovner BW, German PS, Broadhead J, et al. The prevalence and management of dementia and other psychiatric disorders in nursing homes. Int Psychogeriatrics 1990; 2: 13–24

    Article  CAS  Google Scholar 

  3. Swearer JM, Drachman DA, O’Donnell BF, et al. Troublesome and disruptive behaviors in dementia: relationships to diagnosis and disease severity. J Am Geriatr Soc 1988; 36: 784–90

    PubMed  CAS  Google Scholar 

  4. Cohen-Mansfield J. Agitated behaviors in the elderly: II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc 1986; 34: 722–7

    PubMed  CAS  Google Scholar 

  5. Tariot PN, Podgorski CA, Blazina L, et al. Mental disorders in the nursing home: another perspective. Am J Psychiatry 1993; 150: 1063–9

    PubMed  CAS  Google Scholar 

  6. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease: IV. Disorders of behaviour. Br J Psychiatry 1990; 157: 86–94

    Article  PubMed  CAS  Google Scholar 

  7. Pruchno RA, Michaels JE, Potashnik S. Predictors of institutionalization among Alzheimer disease victims with caregiving spouses. J Gerontol 1990; 45 Suppl. 6: S259–66

    PubMed  CAS  Google Scholar 

  8. Giacobini E, Becker R. Present progress and future development in the therapy for Alzheimer’s disease. In: Iqbal K, Wisniewski HM, Winblad B, editors. Alzheimer’s disease and related disorders. New York: Alan R. Liss Inc., 1989: 1121–54

    Google Scholar 

  9. Farlow MR, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992; 268: 2523–9

    Article  PubMed  CAS  Google Scholar 

  10. Rogers SL, Teaneck NJ, Doody R, et al. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer’s disease: results of a 30-week phase III trial [abstract]. Neurology 1996; 46 Suppl. 48: A217

    Google Scholar 

  11. Eaggers SA, Levy R, Sahakian BJ. Tacrine in Alzheimer’s disease. Lancet 1991; 337: 989–92

    Article  Google Scholar 

  12. Knapp MM, Knopman DS, Soloman PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271: 985–91

    Article  PubMed  CAS  Google Scholar 

  13. Cummings JL, Victoroff JI. Noncognitive neuropsychiatric syndromes in Alzheimer’s disease. Neuropsychiatry Neuropsychol Behav Neurol 1990; 3: 140–58

    Google Scholar 

  14. Eichelman B. Toward a rational pharmacotherapy for aggressive and violent behavior. Hosp Community Psychiatry 1988; 39: 31–9

    PubMed  CAS  Google Scholar 

  15. Zweig RM, Ross CA, Hedreen JC, et al. The neuropathology of aminergic nuclei in Alzheimer’s disease. Ann Neurol 1988; 24: 233–42

    Article  PubMed  CAS  Google Scholar 

  16. Zubenko GS, Moossy J. Major depression in primary dementia: clinical and neuropathologic correlates. Arch Neurol 1988; 45: 1182–6

    Article  PubMed  CAS  Google Scholar 

  17. Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990; 47: 209–14

    Article  PubMed  CAS  Google Scholar 

  18. Stewart JT. Managing the care of patients with dementia: how to maximize level of functioning and minimize behavior problems. Postgrad Med 1991; 90: 45–9

    PubMed  CAS  Google Scholar 

  19. Malone ML, Thompson L, Goodwin JS. Aggressive behaviors among the institutionalized elderly. J Am Geriatr Soc 1993; 41: 853–6

    PubMed  CAS  Google Scholar 

  20. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63

    PubMed  CAS  Google Scholar 

  21. Sunderland T, Weingartner H, Cohen RM, et al. Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology (Berl) 1989; 99: 129–33

    Article  CAS  Google Scholar 

  22. Sunderland T, Tariot PN, Newhouse PA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res Rev 1988; 13: 371–89

    Article  Google Scholar 

  23. Devanand DP, Brockington CD, Moody BJ. Behavioral syndromes in Alzheimer’s disease. Int Psychogeriatrics 1992; 4: 161–84

    Google Scholar 

  24. Ancill RJ, Embury GD, MacEwan GW, et al. The use and misuse of psychotropic prescribing for elderly psychiatric patients. Can J Psychiatry 1988; 33: 585–9

    PubMed  CAS  Google Scholar 

  25. Barnes R, Veith R, Okimoto J, et al. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982; 139: 1170–4

    PubMed  CAS  Google Scholar 

  26. Peabody CA, Warner MD, Whiteford HA, et al. Neuroleptics and the elderly. J Am Geriatr Soc 1987; 35: 233–8

    PubMed  CAS  Google Scholar 

  27. Steele C, Lucas MJ, Tune L. Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer’s type: preliminary findings. J Clin Psychiatry 1986; 47: 310–2

    PubMed  CAS  Google Scholar 

  28. Devanand DP, Sackeim HA, Brown RP, et al. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer’s disease. Arch Neurol 1989; 46: 854–7

    Article  PubMed  CAS  Google Scholar 

  29. Wragg RE, Jeste DV. Neuroleptics and alternative treatments: management of behavioral symptoms and psychosis in Alzheimer’s disease and related conditions. Psychiatry Clin North Am 1988; 11: 195–213

    CAS  Google Scholar 

  30. Stotsky B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders. Clin Ther 1984; 6: 546–59

    PubMed  CAS  Google Scholar 

  31. Goldberg RJ, Goldberg JS. Low-dose risperidone for dementia related disturbed behavior in nursing homes [abstract]. APA Annual Meeting 1995; Suppl.: 126

    Google Scholar 

  32. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56(11): 514–8

    PubMed  CAS  Google Scholar 

  33. Patterson JF. A preliminary study of carbamazepine in the treatment of assaultive patients with dementia. J Geriatr Psychiatry Neurol 1988; 1: 21–3

    Article  PubMed  CAS  Google Scholar 

  34. Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer’s outpatients refractory to neuroleptics. J Clin Psychiatry 1990; 51: 115–8

    PubMed  CAS  Google Scholar 

  35. Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994; 42: 1160–6

    PubMed  CAS  Google Scholar 

  36. Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatr Neurol 1993; 6(4): 205–9

    CAS  Google Scholar 

  37. Patel S, Tariot PN. Use of benzodiazepines in behaviorally disturbed patients: risk-benefit ratio. In: Lawlor BA, editor. Behavioral complications in Alzheimer’s disease. Washington, DC: American Psychiatric Press, 1995: 153–70

    Google Scholar 

  38. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262(23): 3303–7

    Article  PubMed  CAS  Google Scholar 

  39. Schneider LS, Sobin PB. Non-neuroleptic medications in the management of agitation in Alzheimer’s disease and other dementia: a selective review. Int J Geriatr Psychiatry 1991; 6: 691–708

    Article  Google Scholar 

  40. Weiler PG, Mungas D, Bernick C. Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatr Neurol 1988; 1: 226–30

    Article  CAS  Google Scholar 

  41. Young RC, Meyer BS. Psychopharmacology. In: Sadavoy J, Lazarus LW, Jarvik LF, editors. Comprehensive review of geriatric psychiatry. Washington, DC: American Psychiatric Press, 1991: 435–67

    Google Scholar 

  42. Ellison JM, Milofsky JE, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatr 1990; 51: 385–6

    CAS  Google Scholar 

  43. Marinkovic D, Totic S, Babinski T, et al. The extrapyramidal side-effects of selective serotonin re-uptake inhibitors. Hum Psychopharmacol 1995; 10: 158–9

    Google Scholar 

  44. Brymer C, Winograd CH. Fluoxetine in elderly patients: is there cause for concern? J Am Geriatr Soc 1992; 40: 902–5

    PubMed  CAS  Google Scholar 

  45. Reynolds III CF, Perel JM, Kupfer DJ, et al. Open-trial response to antidepressant treatment in elderly patients with mixed depression and cognitive impairment. Psychiatry Res 1987; 21: 111–22

    Article  PubMed  Google Scholar 

  46. Sakauye KM, Camp CJ, Ford PA. Effects of buspirone on agitation associated with dementia. Am J Geriatr Psychiatry 1993; 1: 82–4

    Article  Google Scholar 

  47. Levy MA, Burgio LD, Sweet R, et al. A trial of buspirone for the control of disruptive behaviors in community-dwelling patients with dementia. Int J Geriatr Psychiatry 1994; 9: 841–8

    Article  Google Scholar 

  48. Lawlor BA, Radcliffe J, Molchan SE, et al. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer’s disease. Int J Geriatr Psychiatry 1994; 9(1): 55–9

    Article  Google Scholar 

  49. Aisen PS, Johannessen DJ, Marin DB. Trazodone for behavioral disturbance in Alzheimer’s disease. Am J Geriatr Psychiatr 1993; 1(4): 349–50

    Article  Google Scholar 

  50. Simpson DM, Foster D. Improvement in organically disturbed behavior with trazodone treatment. J Clin Psychiatry 1986; 47: 191–3

    PubMed  CAS  Google Scholar 

  51. Shaw SH, Carson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1991; 20: 150–61

    Google Scholar 

  52. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer’s disease. Am J Psychiatry 1989; 146: 577–87

    PubMed  CAS  Google Scholar 

  53. Raskind MA. Management of late-life depression and the non-cognitive behavioral disturbances of Alzheimer’s disease. Psychiatry Clin North Am 1993; 16(4): 815–27

    CAS  Google Scholar 

  54. Thapa PB, Meador KG, Gideon P, et al. Effects of antipsychotic withdrawal in elderly nursing home residents. J Am Geriatr Soc 1994; 42: 280–6

    PubMed  CAS  Google Scholar 

  55. Horwitz GJ, Tariot PN, Mead K, et al. Discontinuation of anti-psychotics in nursing home patients with dementia. Am J Geriatr Psychiatry 1995; 3(4): 290–9

    Article  Google Scholar 

  56. Factor SA, Brown D, Molho ES, et al. Clozapine: a 2-year open trial in Parkinson’s disease patients with psychosis. Neurology 1994; 44: 544–6

    Article  PubMed  CAS  Google Scholar 

  57. Data on file, Lilly Research Laboratories

  58. Schneider LS, Gleason R, Zemansky MF, et al. L-Deprenyl in Alzheimer’s disease [abstract]. Gerontologist 1989; 28: 2A

    Google Scholar 

  59. Tariot PN, Cohen RM, Sunderland T, et al. L-deprenyl in Alzheimer’s disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 1987; 44: 427–33

    Article  PubMed  CAS  Google Scholar 

  60. Larson E, Reifler B, Sumi S, et al. Diagnostic evaluation of 200 elderly outpatients with suspected dementia. J Gerontol 1985; 40(5): 536–43

    PubMed  CAS  Google Scholar 

  61. Rovner BW, Broadhead J, Spencer M, et al. Depression and Alzheimer’s disease. Am J Psychiatry 1989; 146: 350–3

    PubMed  CAS  Google Scholar 

  62. Teri L, Gallagher-Thompson D. Cognitive-behavioral interventions for treatment of depression in Alzheimer’s patients. Gerontologist 1991; 31(3): 413–6

    Article  PubMed  CAS  Google Scholar 

  63. Greenwald BS, Kramer-Ginsberg E, Marin DB, et al. Dementia with coexistent major depression. Am J Psychiatry 1989; 146: 1472–8

    PubMed  CAS  Google Scholar 

  64. Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer’s disease patients with and without depression. Am J Psychiatry 1989; 146: 45–9

    PubMed  CAS  Google Scholar 

  65. Gottfries CG, Karlsson I, Nyth AL. Treatment of depression in elderly patients with and without dementia disorders. Int Clin Psychopharmacol 1992; 6: 55–64

    Article  PubMed  Google Scholar 

  66. Burke WJ, Folks DG, Roccaforte WH, et al. Serotonin reuptake inhibitors for the treatment of coexisting depression and psychosis in dementia of the Alzheimer type. Am J Geriatr Psychiatry 1994; 2(4): 352–4

    Article  Google Scholar 

  67. Nelson JP, Rosenberg DR. ECT treatment of demented elderly patients with major depression: a retrospective study of efficacy and safety. Convuls Ther 1991; 7(3): 157–65

    PubMed  Google Scholar 

  68. Vitiello MV, Prinz PN, Williams DE, et al. Sleep disturbances in patients with mild-stage Alzheimer’s disease. J Gerontol 1990; 45(4): M131–8

    PubMed  CAS  Google Scholar 

  69. Mishima K, Okawa M, Hishikawa Y, et al. Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr Scand 1994; 89: 1–7

    Article  PubMed  CAS  Google Scholar 

  70. Satlin A, Volicer L, Ross V, et al. Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer’s disease. Am J Psychiatry 1992; 149: 1028–32

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Psychiatry and Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA

    C. Andrew Class &  Martin R. Farlow

  2. Department of Psychiatry, University of Southern California at Los Angeles, Los Angeles, California, USA

    Lon Schneider

Authors
  1. C. Andrew Class
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lon Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin R. Farlow
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Class, C.A., Schneider, L. & Farlow, M.R. Optimal Management of Behavioural Disorders Associated with Dementia. Drugs & Aging 10, 95–106 (1997). https://doi.org/10.2165/00002512-199710020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199710020-00003

Keywords

Search

Navigation